Merck: New MAVENCLAD Data at ACTRIMS Forum 2022 Show Favoura

New real-world data show MAVENCLAD (cladribine tablets) had lower annualised relapse rates and longer time to first relapse and time to switch than fingolimod, dimethyl fumarate and teriflunomide

Related Keywords

United States , Norway , Monash , South Australia , Australia , Iceland , United Kingdom , Liechtenstein , Melbourne , Victoria , Canada , Helmut Butzkueven , Monash University , Merck Press , European Commission , Americas Committee For Treatment , Central Clinical School , Department Of Neuroscience , European Union , Serono , Research In Multiple Sclerosis , Americas Committee , Multiple Sclerosis , Generating Learnings In Multiple Sclerosis , Cladribine Tablets Treating , Oral Cladribine , Oral Cladribine Added , Patients With Active Relapsing Disease , Merck Press Releases , Merck , Mavenclad , Data , Actrims , Orum , 022 , Show , Unfavourable , Efficacy , Outcomes , Versus , Mother , Mural , Emts , Tower , Occurrence , Urther , Relapses , Disability , Progression ,